Research

Where You Are:

Moffitt Cancer Center is one of 41 NCI-designated comprehensive cancer centers in the country and the only one based in Florida. The designation is bestowed upon institutions that have significant peer-reviewed research funding; high-quality programs in basic, translational and population research; are dedicated to developing more effective approaches to cancer prevention, diagnosis and therapy; educate health care professionals and the public; and reach out to underserved populations.

Moffitt's impact on cancer research spans basic science, prevention and clinical research with a focus on translating discoveries into better care.

Research Disciplines | Clinical Trials | Research Cores & Technology | Find a Researcher  | Conflict of Interest


Moffitt Research News

Moffitt Cancer Center Researchers Identify Protein Pathway Involved in Brain Tumor Stem Cell Growth

TAMPA, Fla. (Feb. 26, 2015) – Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival. Brain tumor stem cells are believed to play an important role in glioblastoma development and may be possible therapeutic targets. Learn more...

New Human Papillomavirus Vaccine Approved After International Phase 2/3 Trial Involving Moffitt Cancer Center

TAMPA, Fla(Feb. 19, 2015) – Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV).  A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease.  The trial data indicate that if populations are vaccinated with Gardasil 9 approximately 90 percent of all cervical cancers worldwide can be prevented. Learn more...

 

Moffitt Cancer Center Researchers Discover Biological Markers Associated with High-Risk Pancreatic Lesions

TAMPA, Fla(Feb. 2, 2015) – Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths.  Only about 6 percent of individuals with pancreatic cancer will live five years after their diagnosis.  One reason for this high mortality rate is the lack of effective tools to detect pancreatic cancer early enough to allow its surgical removal. Moffitt Cancer Center researchers are now one step closer to devising an approach to detect pancreatic cancer earlier. Learn more...


 
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions